PILA PHARMA AB, a Swedish biotech company, announced it will release its interim report for the second half of 2025 on February 10, 2026, earlier than the initially planned date of February 26, 2026. The change is due to the report's early completion and to facilitate the Board of Directors' and CEO's warrant exercises. PILA PHARMA, based in Malmö, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response in diabetic patients. The company plans to submit a clinical trial application for a dose-finding study in obese patients by the end of Q1 2026. Additionally, PILA PHARMA is exploring licensing opportunities for XEN-D0501 in treating erythromelalgia, a rare inflammatory disease. The company aims to address the growing demand for effective oral treatments for obesity and diabetes, which are global health concerns.

PILA PHARMA AB, a biotech company focused on developing a TRPV1 inhibitor, completed a rights issue of units, including shares and warrants, in the third quarter of 2025. Each warrant allows the holder to subscribe for two new shares at a price set at SEK 1.50, determined as 70% of the average market price, with an exercise period from February 5 to February 15, 2026. If all warrants are exercised, PILA PHARMA could raise approximately SEK 44.87 million before costs. The company's main project, XEN-D0501, targets obesity and type 2 diabetes, with plans to submit a clinical trial application by the end of Q1 2026. The company also explores licensing opportunities for treating erythromelalgia. PILA PHARMA's shares are traded on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB is a Swedish biotech company focusing on developing TRPV1 inhibitors as treatments for obesity, type 2 diabetes, and other inflammatory diseases. The company is hosting an online Q&A session on January 27, 2026, to discuss its preclinical studies and upcoming clinical activities. CEO Gustav H. Gram and Founder Dorte X. Gram will represent the company. PILA PHARMA's drug candidate, XEN-D0501, has shown promise in clinical trials for obesity and diabetes, demonstrating good safety and efficacy. The company plans to submit a clinical trial application for a dose-finding study in obesity by the end of Q1 2026. Obesity and diabetes are global health challenges with significant unmet needs, and PILA PHARMA aims to provide effective oral treatments. The company also holds patents for TRPV1 inhibitors and is exploring licensing opportunities for erythromelalgia and abdominal aorta aneurysm treatments.

PILA PHARMA AB, a Swedish biotech company, announced an agreement with a new clinical Contract Research Organisation to prepare a clinical trial application for obesity treatment, expected to be submitted by the end of Q1 2026. The company completed preclinical studies in rat obesity with inconclusive results, as the formulation used may have affected drug absorption. PILA PHARMA plans to proceed with a clinical dose-finding study for obesity in collaboration with the new CRO. The company's CEO highlighted a successful fundraising effort that allows for accelerating the study. PILA PHARMA focuses on developing TRPV1 inhibitors for obesity and type 2 diabetes, and aims to submit further patents related to its drug candidate XEN-D0501. The company has previously completed two clinical trials showing XEN-D0501's tolerability and efficacy in enhancing insulin response. Additionally, PILA PHARMA holds an orphan drug designation for treating erythromelalgia, a rare disease, and seeks licensing opportunities for this and other conditions.

PILA PHARMA AB, a Swedish biotech company, is developing a novel oral drug, XEN-D0501, based on TRPV1 inhibition for treating obesity and diabetes. The company's CEO, Gustav Hanghøj Gram, appeared on the Market Makers podcast to discuss the company's history, its drug development aspirations, and the potential impact of their oral solution in the obesity market. The obesity market is significant, with over 1 billion people globally, and PILA PHARMA aims to address this with their innovative treatment. XEN-D0501 has shown promise in clinical trials, demonstrating safety and efficacy in enhancing insulin response and reducing cardiovascular risk markers. The company is preparing for further clinical trials to assess the drug's maximal tolerable dose and its effectiveness in reducing body weight. Additionally, PILA PHARMA is exploring licensing opportunities for treating Erythromelalgia and Abdominal Aorta Aneurysm, with XEN-D0501 showing potential benefits in preclinical studies for these conditions. The company is focused on creating a comprehensive data package to support XEN-D0501 as a first-in-class oral drug candidate for obesity and diabetes.

PILA PHARMA AB, a Swedish biotech company, is advancing its investor relations by initiating research coverage with Analyst Group. This includes quarterly equity research updates and analyst comments on financial reports. PILA PHARMA is developing XEN-D0501, a TRPV1 inhibitor, as a treatment for obesity and diabetes. The drug is noted for its potential distinct side-effect profile and simpler synthesis compared to current therapies. The company has completed two phase 2a trials showing the drug's tolerability and efficacy in enhancing insulin response. A new trial, PP-CT03, aims to determine the maximal tolerable dose and assess safety over three months. PILA PHARMA is also exploring licensing opportunities for Erythromelalgia and Abdominal Aorta Aneurysm, with preclinical success in reducing aneurysm growth. The company seeks to expand its visibility in Nordic capital markets through collaborations like the one with Analyst Group.

PILA PHARMA AB, a Swedish biotech company, is developing an oral drug, XEN-D0501, as a TRPV1 inhibitor for obesity and diabetes treatment. The company has been invited to present at the Biotech Showcase during the 2026 J.P. Morgan Healthcare week in San Francisco. CEO Gustav H. Gram will discuss their approach to obesity treatment with American investors. XEN-D0501 is noted for its potential safety and manufacturing advantages over existing treatments. The drug has shown promise in clinical trials, improving insulin response and reducing cardiovascular biomarkers. PILA PHARMA holds patents for TRPV1 antagonists in obesity and diabetes treatment and is pursuing further development and licensing opportunities in related fields, including erythromelalgia and abdominal aorta aneurysm. The global prevalence of obesity and diabetes underscores the demand for innovative treatments like XEN-D0501.

PILA PHARMA AB, a Swedish biotech company focused on developing TRPV1 inhibitors for treating obesity and diabetes, announced that CEO Gustav H. Gram has increased his shareholding by acquiring 40,188 shares at an average price of SEK 2.15 each. Gram now holds 207,484 shares. The purchase was reported to the Swedish Financial Supervisory Authority. PILA PHARMA is advancing its drug candidate XEN-D0501, which has shown promise in clinical trials for obesity and type 2 diabetes, and is preparing for further trials to assess its efficacy and safety. The company also explores licensing opportunities for treating conditions like Erythromelalgia and Abdominal Aorta Aneurysm, where XEN-D0501 has shown potential benefits.

PILA PHARMA AB has initiated preclinical studies on obesity using their drug candidate XEN-D0501 in rats. The studies, conducted by Danish CRO Gubra, aim to demonstrate proof-of-concept by examining the drug's effects on obesity using two rat models: DIO and Zucker rats. A formulation change was made to better suit dosing in obese rats, despite potential uncertainties in drug exposure. Results are expected before the TO2 warrant exercise period, with proceeds intended to fund clinical trials. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases. XEN-D0501, a TRPV1 inhibitor, has shown promise in previous trials and is being prepared for further clinical testing. The company also explores licensing opportunities for related conditions like Erythromelalgia and Abdominal Aorta Aneurysm. Gubra, a Danish company, specializes in preclinical research and drug discovery, focusing on metabolic and fibrotic diseases.

PILA PHARMA AB has announced that Professor Thomas Lutz from the University of Zurich has joined their Scientific Advisory Board. Professor Lutz is renowned for his research in obesity and metabolic diseases, particularly focusing on the hormone amylin's role in metabolism and type 2 diabetes. His work has significantly advanced the understanding of amylin and its interactions with other metabolic controls, contributing to efforts in targeting the amylin system for treating obesity and diabetes. Dorte X. Gram, the company's CSO and founder, expressed enthusiasm about collaborating with Professor Lutz to explore the effects of XEN-D0501 on obesity. PILA PHARMA, based in Malmö, Sweden, is developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and potentially other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials, demonstrating good safety and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The company is preparing further trials to assess the drug's maximal tolerable dose and efficacy in reducing body weight. The company also focuses on licensing opportunities for Erythromelalgia and Abdominal Aorta Aneurysm. XEN-D0501 has been granted orphan drug designation for Erythromelalgia, a painful rare disease, and has shown potential in reducing abdominal aorta aneurysm growth in pre-clinical studies. PILA PHARMA aims to create a comprehensive data package to support XEN-D0501 as a first-in-class oral treatment for obesity and diabetes, addressing significant unmet needs in these areas.

PILA PHARMA AB, a Swedish biotech company, is developing an oral drug targeting TRPV1 for obesity and diabetes treatment. The company announced its participation in two U.S. scientific conferences—ObesityWeek in Atlanta and the American Heart Association Convention in New Orleans—where it will discuss its TRPV1 inhibitor, XEN-D0501. PILA PHARMA holds patents for using TRPV1 inhibitors in treating obesity and diabetes, and is preparing for further clinical trials to assess the drug's efficacy and safety. XEN-D0501 has shown promise in reducing obesity-related health issues and has potential applications in treating erythromelalgia and abdominal aorta aneurysm. The company is also exploring licensing opportunities for these conditions.

PILA PHARMA AB, a Swedish biotech company focused on developing TRPV1 inhibitors for treating obesity and diabetes, announced that CEO Gustav H. Gram has increased his shareholding by acquiring 36,677 shares at an average price of SEK 2.26 per share, bringing his total to 167,296 shares. The transaction was reported to the Swedish Financial Supervisory Authority. PILA PHARMA, listed on Nasdaq First North Growth Market, is based in Malmö and owns a TRPV1 asset, including the development candidate XEN-D0501, which has shown promise in treating obesity, type 2 diabetes, and potentially other inflammatory diseases. The company has completed two phase 2a trials demonstrating the safety and potential efficacy of XEN-D0501. It is preparing a new trial to assess the drug's maximal tolerable dose and efficacy in weight reduction. PILA PHARMA also explores licensing opportunities for treating Erythromelalgia and Abdominal Aorta Aneurysm. The company aims to develop XEN-D0501 as a first-in-class oral treatment for obesity and diabetes, addressing significant global health challenges.